Lactobacillus gasseri
Also called L. gasseri, Lactobacillus paragasseri, SBT2055, LG2055, BNR17, CP2305.
Best grade C across 8 graded outcomes Other Last checked
We earn a commission if you buy through links on this page. It never changes our grades or rankings. How we make money →
The short answer
From 13 sourcesL. gasseri trials are strain-specific and mostly run by the strain makers. In Japan, fermented milk with SBT2055 cut belly fat by 4.6% to 8.5% over 12 weeks, and BNR17 capsules lowered visceral fat in Korea. Heat-killed CP2305 eased stress and menopause scores. Other strains were tested for indigestion, allergies and colds.
Every graded outcome on this page
8 rows · line = participants- CGrade CAbdominal fat at lower probiotic dosesBody fatn 210
- CGrade CCommon cold symptoms in healthy adultsColdsn 200
- CGrade CFunctional dyspepsia without H. pylori infectionIndigestionn 116
- CGrade CVisceral fat and waist size in adults with obesityBody fatn 90
- CGrade CAbdominal fat in adults with excess weightBody fatn 87
- CGrade CMild menopausal symptomsMenopausen 80
- CGrade CAnxiety and sleep in students under exam stressStress and sleepn 60
- DGrade DSeasonal allergy quality of lifeAllergiesn 173
- 5 more graded outcomes, in the evidence chapter
Key facts
- What it is
- A lactic acid bacterium; each trial used a named strain, and SBT2055 is now classified as L. paragasseri110
- Belly fat (SBT2055)
- Visceral fat fell 4.6% to 8.5% from baseline over 12 weeks in two Japanese fermented-milk trials; not in controls34
- Visceral fat (BNR17)
- High-dose capsules lowered visceral fat vs placebo in 90 Korean adults5
- Stress and sleep (CP2305)
- Heat-killed tablets lowered anxiety and improved sleep vs placebo in 60 students6
What it is
Lactobacillus gasseri is a lactic acid bacterium used as a probiotic; trials test named strains such as SBT2055, BNR17 and CP2305.
Forms, side by side
3 forms named in our sources. The rest show what our data holds, and say plainly where it holds nothing yet.
Lactobacillus gasseri forms compared
3 forms| 3 forms | Fermented milk or yogurt with a named strain (SBT2055, OLL2716) | Live-bacteria capsules (BNR17, SBT2055, KS-13 blends) | Heat-inactivated tablets (CP2305) |
|---|---|---|---|
| Absorption in people | Not absorbed; acts in the gut. Fat trials measured abdominal fat by CT scan.34 | Not absorbed; acts in the gut.5 | Not absorbed; these are non-living cells.67 |
| GI tolerance | The cited abstracts do not report adverse events; Health Canada lists general probiotic cautions.341 | Blood markers did not differ from placebo over 12 weeks of BNR17.5 | The abstracts do not report adverse events; used for 24 weeks in students and six menstrual cycles in women.67 |
| Studied for | Belly fat, indigestion | Visceral fat, seasonal allergies, colds | Stress, sleep, menopausal symptoms |
- Fermented milk or yogurt with a named strain (SBT2055, OLL2716)
- Live-bacteria capsules (BNR17, SBT2055, KS-13 blends)
- Heat-inactivated tablets (CP2305)
What the human research says
Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.
Trial map
8 graded outcomes, largest study firstAll 8 graded outcomes found an improvement. The largest, a 2013 randomized trial of 210 people on abdominal fat at lower probiotic doses, found an improvement.
1Abdominal fat at lower probiotic doses
Improved · Grade C · RCT, 210 people, 2013
Healthy Japanese adults with large visceral fat areas
Dose, result and source| Outcome | Found | People | Study | Who was studied |
|---|---|---|---|---|
| Abdominal fat at lower probiotic doses | Improved | 210 | Grade C · RCT, 2013 | Healthy Japanese adults with large visceral fat areas |
| Common cold symptoms in healthy adults | Improved | 200 | Grade C · RCT, 2023 | Healthy Japanese adults (191 analysed) |
| Seasonal allergy quality of life | Improved | 173 | Grade D · RCT, 2017 | US adults with self-reported seasonal allergies (mean age 27) |
| Functional dyspepsia without H. pylori infection | Improved | 116 | Grade C · RCT, 2017 | Japanese adults with functional dyspepsia and no H. pylori infection (106 analysed per protocol) |
| Visceral fat and waist size in adults with obesity | Improved | 90 | Grade C · RCT, 2018 | Korean adults aged 20 to 75 with BMI 25 to 35 |
| Abdominal fat in adults with excess weight | Improved | 87 | Grade C · RCT, 2010 | Japanese adults with BMI 24.2-30.7 and high visceral fat (43 active, 44 control) |
| Mild menopausal symptoms | Improved | 80 | Grade C · RCT, 2022 | Women aged 40 to 60 with mild menopausal symptoms |
| Anxiety and sleep in students under exam stress | Improved | 60 | Grade C · RCT, 2019 | Japanese medical students preparing for the national exam (41 men, 19 women) |
Every graded row
8 rowsShowing 8 of 8 outcomes. Human trials only.
CGrade CAbdominal fat at lower probiotic dosesBody fatLess belly fat while consumedRCT
n 210 · 2013
Improved Visceral fat area fell 8.5% and 8.2% from baseline at the two strain doses at week 12, with BMI and waist also down; the control group did not change, and the effects faded within 4 weeks of stopping.
- Design
- RCT, n = 210, 2013
- Population
- Healthy Japanese adults with large visceral fat areas
- Form
- Fermented milk with SBT2055 at two concentrations or none
- Dose
- 200 g fermented milk a day (about 100 million CFU a day or more)
- Duration
- 12 weeks, then 4 weeks off
- Source
- Reference 4 · PubMed 23614897 (opens PubMed)
CGrade CCommon cold symptoms in healthy adultsColdsFewer self-rated cold symptomsRCT
n 200 · 2023
Improved The share of "without symptoms" responses was higher than placebo for runny nose, blocked nose, sneezing, sore throat, hoarseness and chills.
- Design
- RCT, n = 200, 2023
- Population
- Healthy Japanese adults (191 analysed)
- Form
- SBT2055 capsules (now L. paragasseri)
- Dose
- Three capsules a day
- Duration
- 12 weeks
- Source
- Reference 10 · PubMed 37892533 (opens PubMed)
CGrade CFunctional dyspepsia without H. pylori infectionIndigestionMore symptom clearanceRCT
n 116 · 2017
Improved Major dyspepsia symptoms cleared in 35.3% vs 17.3% on placebo (p = 0.048); the overall impression of stomach symptoms was only a trend (p = 0.073).
- Design
- RCT, n = 116, 2017
- Population
- Japanese adults with functional dyspepsia and no H. pylori infection (106 analysed per protocol)
- Form
- Yogurt with OLL2716 (placebo: yogurt without it)
- Dose
- Daily yogurt
- Duration
- 12 weeks
- Source
- Reference 8 · PubMed 28768250 (opens PubMed)
CGrade CVisceral fat and waist size in adults with obesityBody fatLess visceral fat at the high doseRCT
n 90 · 2018
Improved Visceral fat fell vs placebo on the high dose (difference -21.6 cm2, P = .012); waist size fell from baseline on both doses. Blood markers did not differ.
- Design
- RCT, n = 90, 2018
- Population
- Korean adults aged 20 to 75 with BMI 25 to 35
- Form
- BNR17 capsules
- Dose
- 1 billion or 10 billion CFU a day
- Duration
- 12 weeks
- Source
- Reference 5 · PubMed 29688793 (opens PubMed)
CGrade CAbdominal fat in adults with excess weightBody fatLess belly fatRCT
n 87 · 2010
Improved Visceral fat area fell 4.6% and subcutaneous fat 3.3% from baseline, with body weight down 1.4% (1.1 kg); none of these fell in the control group. Results are reported as changes from baseline.
- Design
- RCT, n = 87, 2010
- Population
- Japanese adults with BMI 24.2-30.7 and high visceral fat (43 active, 44 control)
- Form
- Fermented milk with SBT2055 (control: same milk without it)
- Dose
- 200 g fermented milk a day
- Duration
- 12 weeks
- Source
- Reference 3 · PubMed 20216555 (opens PubMed)
CGrade CMild menopausal symptomsMenopauseMilder symptom scoresRCT
n 80 · 2022
Improved Total, vasomotor (hot-flush) and psychological menopause scores improved more than placebo; the share of women with relief was 75.0% vs 55.0% (p = 0.0594).
- Design
- RCT, n = 80, 2022
- Population
- Women aged 40 to 60 with mild menopausal symptoms
- Form
- Heat-inactivated CP2305 tablets
- Dose
- Tablets daily (amount not stated in the abstract)
- Duration
- Six menstrual cycles
- Source
- Reference 7 · PubMed 35565662 (opens PubMed)
CGrade CAnxiety and sleep in students under exam stressStress and sleepLower anxiety, better sleepRCT
n 60 · 2019
Improved Anxiety and sleep disturbance scores fell more than with placebo; sleep EEG showed shorter sleep latency, and salivary chromogranin A, a stress marker, was lower.
- Design
- RCT, n = 60, 2019
- Population
- Japanese medical students preparing for the national exam (41 men, 19 women)
- Form
- Heat-inactivated CP2305 tablets
- Dose
- One tablet a day
- Duration
- 24 weeks
- Source
- Reference 6 · PubMed 31405122 (opens PubMed)
DGrade DSeasonal allergy quality of lifeAllergiesBetter allergy quality of lifeRCT
n 173 · 2017
Improved The allergy quality-of-life score improved by 0.68 vs 0.19 on placebo from baseline to pollen peak (P = 0.0092); IgE and regulatory T cells did not differ.
- Design
- RCT, n = 173, 2017
- Population
- US adults with self-reported seasonal allergies (mean age 27)
- Form
- L. gasseri KS-13 + B. bifidum G9-1 + B. longum MM-2 capsules (a blend)
- Dose
- 2 capsules a day, 1.5 billion CFU each
- Duration
- 8 weeks of spring allergy season
- Source
- Reference 9 · PubMed 28228426 (opens PubMed)
What the numbers add up to
Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.
Almost all maker research
Fat loss faded after stopping
In the 210-person SBT2055 trial, belly-fat reductions faded within 4 weeks of stopping the fermented milk.4
Studied doses
Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.
Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.
Doses studied in human trials
Interactions and safety
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
What Lactobacillus gasseri meets
2 cited rows 2 tested togetherMedicines 2
Supplements and foods 2
- Drug label or FDA notice
- Tested together in a graded trial
Choose a medicine or supplement above to read its cited rows here.
Also cited: 2 tested together
Antibiotics
Drug labelDrug label or FDA notice
Antibiotics, for example any oral antibiotic course: Health Canada's probiotics monograph directs that bacterial probiotics be used at least 2–3 hours before or after antibiotics.
Source 1, Health Canada, Natural and Non-prescription Health Products Directorate (2026)
Immunosuppressive treatment
Drug labelDrug label or FDA notice
Immunosuppressive treatment, for example long-term corticosteroids: Health Canada lists an immune-compromised condition, including long-term corticosteroid treatment, as a contraindication for probiotics; NCCIH and ODS say harmful effects are more likely in people with compromised immune systems.
Source 1, Health Canada, Natural and Non-prescription Health Products Directorate (2026); Source 2, National Center for Complementary and Integrative Health (NCCIH) (2019); Source 12, NIH Office of Dietary Supplements (2025)
Bifidobacterium bifidumBifidobacterium bifidum page
Tested together
Seasonal allergy quality of life. Graded on the Lactobacillus gasseri page; tested together is not a claim that they work better together.
Bifidobacterium longumBifidobacterium longum page
Tested together
Seasonal allergy quality of life. Graded on the Lactobacillus gasseri page; tested together is not a claim that they work better together.
Interactions
2 agents| Agent | What the source says | Evidence |
|---|---|---|
| Medicines2 | ||
| Antibioticse.g. any oral antibiotic course | Health Canada's probiotics monograph directs that bacterial probiotics be used at least 2–3 hours before or after antibiotics.1 | Drug label |
| Immunosuppressive treatmente.g. long-term corticosteroids | Health Canada lists an immune-compromised condition, including long-term corticosteroid treatment, as a contraindication for probiotics; NCCIH and ODS say harmful effects are more likely in people with compromised immune systems.1212 | Drug label |
Check with what you take
Kept on this device onlyAdd what you take. We list every interaction our evidence profiles cite between Lactobacillus gasseri and your picks, and between your picks.
- Loading names…
Add a supplement or medicine you take to check it against Lactobacillus gasseri.
Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.
Who should be careful
4 groups- Immune-compromised conditions
- Health Canada's probiotic monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma, or long-term corticosteroid treatment).1
- Fever or severe gut symptoms
- Health Canada: ask a health care practitioner before use if you have fever, vomiting, bloody diarrhoea or severe abdominal pain, and stop if digestive upset occurs, worsens or lasts beyond 3 days.1
How to read the label
What to check on the Supplement Facts panel.
How to read the label
2 checksLook for the strain code
Where to buy Lactobacillus gasseri
Products from brands we partner with that contain Lactobacillus gasseri. Check the amount per serving against the doses studied above, and the label for other ingredients.
Lactobacillus gasseri products from partner brands
1 product Paid links · we earn a commission- HerbsProKyolic Kyo-Dophilus, 180 Caps
1 capsule: 1.5 billion cells of a blend of L. gasseri, B. bifidum and B. longum (strain codes not shown on the HerbsPro listing); the 2017 allergy trial gave 2 capsules a day of a similar 3-species blend
$33.82one-timeChecked Oct 15, 2026
Frequently asked questions
Short answers to common questions; the numbers link to the sources below.
Common questions
6 answersDoes L. gasseri help with weight loss?
Can L. gasseri help with stress or sleep?
Does it help digestion?
Yogurt with OLL2716 cleared major indigestion symptoms more often than placebo yogurt (35.3% vs 17.3%) in a per-protocol analysis.8
Is L. gasseri safe?
Can it be used with antibiotics?
Sources
13 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.
Sources cited on this page
13 sources- 1Probiotics (Natural Health Product monograph, April 24, 2026)Guideline Health Canada, Natural and Non-prescription Health Products Directorate, 2026 · webprod.hc-sc.gc.ca
- 2Probiotics: Usefulness and SafetyFact sheet National Center for Complementary and Integrative Health (NCCIH), 2019 · nccih.nih.gov
- 3Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial.RCT Eur J Clin Nutr, 2010 · PMID 20216555
- 4Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial.RCT Br J Nutr, 2013 · PMID 23614897
- 5Lactobacillus gasseri BNR17 Supplementation Reduces the Visceral Fat Accumulation and Waist Circumference in Obese Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.RCT J Med Food, 2018 · PMID 29688793
- 6Health Benefits of Lactobacillus gasseri CP2305 Tablets in Young Adults Exposed to Chronic Stress: A Randomized, Double-Blind, Placebo-Controlled Study.RCT Nutrients, 2019 · PMID 31405122
- 7Effects of Lactobacillus gasseri CP2305 on Mild Menopausal Symptoms in Middle-Aged Women.RCT Nutrients, 2022 · PMID 35565662
- 8The Ameliorating Effect of Lactobacillus gasseri OLL2716 on Functional Dyspepsia in Helicobacter pylori-Uninfected Individuals: A Randomized Controlled Study.RCT Digestion, 2017 · PMID 28768250
- 9Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial.RCT Am J Clin Nutr, 2017 · PMID 28228426
- 10Lactobacillus paragasseri SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial.RCT Nutrients, 2023 · PMID 37892533
- 11Daily consumption of Lactobacillus gasseri CP2305 improves quality of sleep in adults - A systematic literature review and meta-analysis.Meta-analysis Clin Nutr, 2023 · PMID 37413809
- 12Probiotics: Fact Sheet for Health Professionals (updated March 25, 2025)Fact sheet NIH Office of Dietary Supplements, 2025 · ods.od.nih.gov
- 13Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or YeastSafety communication U.S. Food and Drug Administration, 2023 · fda.gov
What changed
Every dated change to this page: what changed, who made it and why.
Change log
2 entries| Date | Change | Who and why |
|---|---|---|
| interactions, who should avoid, FAQ, evidence notes, sources | Added antibiotic-spacing and immunosuppressant interactions from the Health Canada monograph, NCCIH and NIH ODS; added a pregnancy and breastfeeding note (NCCIH, ODS); cited the FDA 2023 preterm-infant safety communication; added the 2023 CP2305 sleep meta-analysis (PMID 37413809) to the stress row notes and sleep FAQ; new antibiotics FAQ. | Writer: Kymata Health EditorialTrigger: A–Z page audit |
| all | Initial editorial evidence review. Every PMID checked against NCBI E-utilities esummary (title, year, journal; none retracted) and each cited abstract read; numbers taken from the abstracts (full text or registry used only where noted). Funding disclosed per study: Snow Brand Milk Products / Megmilk Snow Brand authors (2010, 2013; 2023 no external funding, three employee authors), Asahi Group Holdings / Asahi Quality & Innovations (2019, 2022), Meiji affiliation (2017 dyspepsia), Biofood CRO (2018); the 2017 allergy blend abstract does not name a funder. Safety rows use only Health Canada and NCCIH. Where to buy: Kyolic Kyo-Dophilus (label checked 2026-10-15). | Writer: Kymata Health EditorialTrigger: new page |
Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.